๋ฉ๊ธ๋ฃจ๋ฏผ ์ํฐ๋ชจ๋์์ดํธ
๋ฉ๊ธ๋ฃจ๋ฏผ ์ํฐ๋ชจ๋์์ดํธ๋ ๊ฐ์์ **๋ฆฌ์๋งํธ๋ชจ์ถฉ์ฆ(Leishmaniasis)** ์น๋ฃ์ ์ฌ์ฉ๋๋ 5๊ฐ ์ํฐ๋ชฌ ํํฉ๋ฌผ์ ๋๋ค(์๋กํธ๋ฆฌ๋๊ณผ ๋ณ์ฉ ๋๋ ๋จ๋ ์ฌ์ฉ). * **์์ ์์ **: ๋ณ์์ฒด๋ฅผ ์์ ํ ์ ๊ฑฐํ๊ธฐ๋ ์ด๋ ค์ฐ๋ฉฐ, ์น๋ฃ ๊ธฐ๊ฐ์ด ๊ธธ๊ณ ๋น์ฉ์ด ๋ง์ด ๋ค ์ ์์ต๋๋ค. * **๋ด์ฑ**: ์น๋ฃ์ ๋ํ ๋ด์ฑ์ด ๋ณด๊ณ ๋์์ผ๋ฉฐ, ์๋กํธ๋ฆฌ๋๊ณผ์ ๋ณ์ฉ์ด ๋ด์ฑ ๋ฐ์ ์ํ์ ์ค์ผ ์ ์์ต๋๋ค. * **์์ ์ฑ**: ์ฌ์ฅ, ๊ฐ ๋๋ ์ ์ฅ ๊ธฐ๋ฅ ๋ถ์ ํ์์๊ฒ๋ ์๋์ ๊ธ๊ธฐ์ด๋ฉฐ ๊ทน๋์ ์ฃผ์๊ฐ ํ์ํฉ๋๋ค.
์์ฉ ๊ธฐ์ : Meglumine antimoniate selectively inhibits leishmanial enzymes required for **glycolytic and fatty acid oxidation** โ disruption of parasite bioenergetics โ decreased ATP production โ death of the organism. * **Synergy**: When used with allopurinol (a leishmaniostatic agent that disrupts RNA synthesis), the combination provides synergistic efficacy and helps prevent the emergence of resistant strains. * **Mechanistic Pearl**: While the exact mechanism remains partially elucidated, it is widely believed that pentavalent antimony (SbV) acts as a prodrug and is reduced to the more toxic and active **trivalent antimony (SbIII)** within the acidic environment of the macrophage phagolysosome, where the amastigotes reside.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Leishmaniosis (off-label) ยท 50 mg/kg ยท SC ยท q24h ยท 3-4 weeks ยท Use with extreme caution; cats may be more sensitive to toxicity.
- Leishmaniasis (First line treatment) ยท 75-100 mg/kg SC once daily for 4-8 weeks, with allopurinol (10 mg/kg PO twice daily for at least 6-12 months. ยท SC ยท q24h ยท 4-8 weeks ยท Used in combination with allopurinol.
- Leishmaniasis ยท 100 mg/kg SC daily for 3-4 weeks; better results are obtained with longer durations (4-6 weeks) of treatment. Protocol with allopurinol may reduce relapse rates: meglumine antimoniate as above with allopurinol at 20-40 mg/kg PO daily for a minimum of 3 weeks. Followed with long-term treatment with allopurinol (alone) at 20-40 mg/kg PO daily or intermittently (one week treatment per month). ยท SC ยท q24h ยท 3-6 weeks ยท Longer duration (4-6 weeks) yields better results.
- Leishmaniasis ยท 100 mg/kg/day SC until resolution; with allopurinol at 20 mg/kg PO q12h for 9 months. ยท SC ยท q24h ยท Until resolution ยท Used in combination with allopurinol.
- Leishmaniosis ยท 75-100 mg/kg ยท SC ยท q24h (or divided q12h) ยท 3-4 weeks ยท Often used in combination with allopurinol (10 mg/kg PO q12h for 6-12 months).
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Previous hypersensitivity to meglumine antimoniate
- Severe renal, hepatic, or cardiac failure (relative contraindication; weigh risks vs. benefits)
- Severe renal impairment
- Hepatic failure
- Cardiac disease
์ด์๋ฐ์
- Injection site reactions (cutaneous abscesses, cellulitis, pain)
- Lethargy
- Gastrointestinal effects (inappetence, vomiting)
- Transient increases in liver enzymes
- Nephrotoxicity (tubular damage, proximal tubule cell vacuolization, coagulative necrosis)
- Pain and swelling at the injection site
- Nephrotoxicity (proteinuria, elevated BUN/creatinine)
- Anorexia
- Vomiting
- Hepatotoxicity (rare)
- Myalgia/arthralgia
์ฝ๋ฌผ ์ํธ์์ฉ
- Agents that can prolong QT interval (e.g., tricyclic antidepressants, disopyramide, quinidine, procainamide) ยท Meglumine antimoniate may prolong QT interval further with increased risk for arrhythmias
- Aminoglycosides ยท Increased risk of nephrotoxicity ยท major
- NSAIDs ยท Increased risk of nephrotoxicity ยท moderate
๋ชจ๋ํฐ๋ง
- Efficacy (PCR preferred)
- CBC (baseline and periodic)
- Liver enzymes (baseline and periodic)
- Renal function tests (serum creatinine, BUN) (baseline and periodic)
- Serum lipase and amylase (baseline and periodic)
- Urinalysis (baseline and periodic)
- Urinalysis (specifically for proteinuria/UPC ratio)
- BUN and Creatinine
- Liver enzymes (ALT, AST, ALP)
- Complete Blood Count (CBC)
- Clinical signs of injection site reactions
๊ณผ์ฉ๋
No specific overdose information is available. Depending on the dosage, a single massive overdose could potentially cause **renal, hepatic, pancreatic, and hematologic toxicity**. Clinically, **gastrointestinal effects (severe vomiting)** and **profound lethargy** would be the most likely immediate outcomes. *Management*: Observe the patient closely, provide supportive care (IV fluids to protect renal function), and contact an animal poison control center for further guidance.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.